why-i-o-optimise

Get in touch

Lung cancer is the leading cause of cancer mortality worldwide.¹ Significant advances in the understanding of the complexity of lung tumour biology have resulted in the development of novel therapeutic agents evolving beyond chemotherapy for patients who meet appropriate criteria (eg, targeted drugs). The advent of immuno-oncology (I-O) has resulted in a paradigm shift in the treatment of lung cancers*.

There are a range of treatment options available (eg, chemotherapy, targeted drugs and I-O therapy) for the care of patients. Oncologists and other healthcare professionals require evidence to support informed therapy selection, while payers and regulators require evidence that supports the value of innovative therapies. The change in the treatment landscape highlights the need for ongoing insights that deliver comprehensive clinical and economic data.

Real-world databases^†, if maintained and kept up to date, are a ready source of observational data from routine clinical practice that can be explored in order to provide stakeholders with additional insights that may complement clinical trial data.
By partnering with healthcare systems across countries to optimise existing data sources, I-O Optimise generates timely, ongoing and complementary insights on the evolving treatment landscape for thoracic malignancies* to deliver value to oncologists and other healthcare professionals, patients, academic researchers, payers and regulators.

*I-O Optimise is generating data for non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma.
^† Secondary data that are originally generated by healthcare professionals as part of care delivery (electronic medical records) or for managing treatment reimbursement (claims), or that governments and non-governmental organisations use to manage population health (registries).
Reference:
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.